Background Post-transplant hepatitis B virus (HBV) reinfection is one of the major problems facing patients who undergo HBV-related liver transplantation (LT). We analyzed the clinical impact of serum hepatitis B core-related antigen (HBcrAg) on HBV reinfection in post-LT patients with HBV-related liver diseases. Methods Serum hepatitis B surface antigen (HBsAg), HBV DNA, and HBcrAg were measured over time in 32 post-LT patients. Twenty-one out of 32 patients had HCC at LT. The effects of HBcrAg, hepatocellular carcinoma (HCC) recurrence, and HBs gene mutation on HBV reinfection and withdrawal from hepatitis B immune globulin (HBIG) were analyzed. Results Sixteen out of 32 patients (50 %) were positive for HBcrAg even though only six patients were thought to have experienced HBV reinfection based on reappearance of either HBV DNA or HBsAg during a median follow-up time of 75 months. Three of these six patients who became re-infected with HBV experienced HCC recurrence after LT. The HBV DNA reappearance rate was significantly higher in patients with HCC recurrence after LT (p \ 0.001). Two HBV re-infected patients without HCC recurrence had HBs gene mutations G145R and G145A, respectively. Anti-HBs antibody development rate by HB vaccination was similar between HBcrAg-positive and negative patients (p = 0.325). Conclusions HBV reinfection is more common than is usually considered based on conventional measurement of HBsAg and HBV DNA. HCC recurrence and mutations in the HBV S gene were associated with HBV reinfection after LT.
Abstract Background Post-transplant hepatitis B virus (HBV) reinfection is one of the major problems facing patients who undergo HBV-related liver transplantation (LT). We analyzed the clinical impact of serum hepatitis B core-related antigen (HBcrAg) on HBV reinfection in post-LT patients with HBV-related liver diseases. Methods Serum hepatitis B surface antigen (HBsAg), HBV DNA, and HBcrAg were measured over time in 32 post-LT patients. Twenty-one out of 32 patients had HCC at LT. The effects of HBcrAg, hepatocellular carcinoma (HCC) recurrence, and HBs gene mutation on HBV reinfection and withdrawal from hepatitis B immune globulin (HBIG) were analyzed. Results Sixteen out of 32 patients (50 %) were positive for HBcrAg even though only six patients were thought to have experienced HBV reinfection based on reappearance of either HBV DNA or HBsAg during a median follow-up time of 75 months. Three of these six patients who became re-infected with HBV experienced HCC recurrence after LT. The HBV DNA reappearance rate was significantly higher in patients with HCC recurrence after LT (p \ 0.001). Two HBV re-infected patients without HCC recurrence had HBs gene mutations G145R and G145A, respectively. Anti-HBs antibody development rate by HB vaccination was similar between HBcrAg-positive and negative patients (p = 0.325).
Conclusions HBV reinfection is more common than is usually considered based on conventional measurement of HBsAg and HBV DNA. HCC recurrence and mutations in the HBV S gene were associated with HBV reinfection after LT. 
Introduction
Liver transplantation (LT) is an established treatment for life-threatening liver disease. Hepatitis B virus (HBV) reinfection of the liver graft is one of the most important risk factors for patients who have undergone LT for HBVrelated liver disease and leads to severe graft failure and poor prognosis [1, 2] . Prior to the development of effective immune prophylaxis and antiviral agents, the HBV reinfection rate was greater than 80 %, and the mortality rate was 50 % at 2 years [3] . The prophylactic use of long-term hepatitis B immune globulin (HBIG) and nucleos(t)ide analogue (NA) combination therapy has markedly reduced the risk of HBV reinfection and improved the outcome of LT for HBV related liver disease [4] [5] [6] [7] . Previous studies have reported that the HBV reinfection rate in liver transplant patients treated with combination prophylaxis with HBIG and NA is approximately 10 % [7] [8] [9] [10] . Long-term administration of HBIG entails several issues including the high cost of the therapy, so several attempts have been made to discontinue HBIG administration and replace it with HB vaccination or NA therapy, but it remains unclear how long HBIG administration should be continued and how to accurately monitor HBV reinfection status after HBIG discontinuation [11] [12] [13] [14] . Serum HBV viral markers are followed to confirm HBV recurrence after LT, as indicated by the reappearance of hepatitis B surface antigen (HBsAg) or HBV DNA. However, previous reports have shown that NA therapy masks the appearance of HBV DNA regardless of the presence of intrahepatic HBV covalently closed circular (ccc) DNA [15] . HBV recurrence is also highly associated with post-LT recurrence of hepatocellular carcinoma (HCC) [9] , so close virological monitoring is required for patients with HBV-related liver disease who undergo LT.
Recently, a new assay was developed to detect hepatitis B core-related antigen (HBcrAg). HBcrAg consists of the hepatitis B core antigen (HBcAg), hepatitis B e antigen (HBeAg), and a 22 kDa pre-core protein encoded by the pre-core/core gene. HBcrAg has been reported as a serum marker that could be used to estimate the extent of the intrahepatic HBV cccDNA pool through the viral proteins transcribed through messenger RNA from cccDNA [16, 17] . Previous reports showed that serum HBcrAg was detectable in post-LT patients without HBV recurrence [18, 19] ; however, the relationship between HBcrAg and HBV recurrence after LT has not been described. This study aimed to investigate HBV reinfection status and the result of long-term combination prophylaxis by measuring serum HBcrAg in post-LT patients.
Methods

Patients
From March 2001 to October 2013, 53 patients with HBVrelated liver diseases underwent living donor LT at Hiroshima University Hospital. Thirty-two out of the 53 patients had stored sera available to measure HBcrAg from at least five time points and were enrolled in the study. Patient characteristics are shown in Table 1 . The patient population included 25 males and seven females, and the median age was 52 years (range 20-66 years). The median duration of post-LT follow-up was 75 months (range 20-167 months). HCC was present at LT in 21 patients (65.6 %). HCC was diagnosed by preoperative computed tomography or magnetic resonance imaging in 19 patients, and by pathological examination of the explant in two patients. One patient was co-infected with genotype 1b hepatitis C virus (HCV). At the time of LT, all 32 patients had been treated with antiviral therapy consisting of lamivudine (LAM), LAM plus adefovir (ADV) or entecavir (ETV), and the HBV viral load was detectable in 12 patients (37.5 %), with a median level of 4.8 log copies/mL (range 2.2-8.4 log copies/mL).
All patients were treated with HBIG and NA for HBV prophylaxis after LT. Patients were given 10,000 units of HBIG intravenously during the anhepatic phase of the operation and on the day following transplantation. Thereafter, they were given 1000-2000 units of HBIG every 1-4 weeks to maintain serum anti-hepatitis B surface antibody (HBsAb) titer levels above 100 mIU/mL. Patients were administered HBIG for at least 2 years after LT, and then recombinant HB vaccine was administered intramuscularly every 4 weeks at the same time as HBIG administration. HBIG was stopped when the HBsAb titer was estimated to be maintained by the HB vaccine alone. HBV markers were monitored after cessation of HBIG, and HBIG was restarted if HBsAb titer decreased below 100 mIU/mL.
Measurement of virological markers
HBsAg and HBsAb levels were measured by the chemiluminescence enzyme immunoassay (CLEIA) method using a commercially available enzyme immunoassay kit (Lumipulse, Fuji rebio, Inc., Tokyo, Japan). HBV DNA level was measured using a transcription-mediated J Gastroenterol (2017) 52:366-375 367 amplification assay (TMA) (SRL, Tokyo, Japan), polymerase chain reaction (PCR) assay (Amplicor HBV Monitor assay; Roche Diagnostics, Tokyo, Japan), or real-time PCR assay (COBAS TaqMan HBV Test; Roche Diagnostics). The detectable ranges for HBV DNA quantitation using these methods are from 3.7 to 8.7 LGE/mL, 2.6-7.6 log copies/mL and 1.8-8.8 log copies/mL, respectively. HBV reinfection was diagnosed in the event of positive serum HBsAg or detectable HBV DNA. The serum HBcrAg level was monitored from a median of 41 months (range 1-127 months) after LT by a CLEIA HBcrAg assay kit with a fully automated analyzer system (Lumipulse System, Fujirebio Inc., Tokyo, Japan). The detection limit for the assay was 3.0 log U/mL. The serum HBcrAg level was measured at least five times in each patient. Patients were considered HBcrAg-positive when HBcrAg was detectable at one or more time points.
Sequence analysis of the HBV S gene HBV DNA was extracted from 100 ll of stored serum samples using the Smitest R&D (Genome Science Laboratories, Tokyo, Japan) and dissolved in 20 ll of sterile water. The extracted DNA was then amplified by PCR using 1 ll of DNA as a template. PCR was performed in 25 ll of reaction mixture containing 2.5 mM MgCl 2 , 0.4 mM each deoxynucleoside triphosphate (dNTP), 20 pmol of each primer, and 1.25 units of LA Taq (Takara Bio Inc., Shiga, Japan) with the buffer supplied by the manufacturer. The primers used in this study were full1 (5 0 -CCGGAAAGCTTGAGCTCTTCTTTTTCACCTCTG CCTAATCA-3 0 ) and full2 (5 0 -CCGGAAAGCTTGA GCTCTTCAAAAAGTTGCATGGTGCTGG-3 0 ). The PCR protocol was as follows: initial denaturation at 94°C for 2 min and 35 cycles of denaturation at 94°C for 1 min, annealing at 58°C for 1 min, extension at 72°C for 2 min, and final extension at 72°C for 7 min. After amplification, the PCR products were gel purified with the QIAquick gel extraction kit (Qiagen, Hilden, Germany) and sequenced using the dye terminator cycle sequencing kit (Applied Biosystems, Foster City, CA). Sequence analysis was performed on an ABI Prism 3100 Avant Genetic Analyzer (Applied Biosystems).
Statistical analysis
Cumulative HBV DNA reappearance-free survival in patients with HCC recurrence was analyzed using the Kaplan-Meier method. The log-rank test was used to compare survival curves between the groups selected. Statistical analysis was performed using SPSS ver.22.0 (SPSS, Chicago, IL). The obtained nucleotide and amino acid sequences were compared with our laboratory strain (GenBank accession number AB206816) [20] .
Results
HBV reinfection after liver transplantation
HBV DNA reappeared in the serum in six out of the 32 patients (18.8 %) during the observation period after LT. The cumulative rates of HBV DNA reappearance were 0, 9.4, and 18.8 % at 2, 5, and 8 years after LT, respectively (Fig. 1) . Characteristics of the six patients with HBV DNA reappearance are shown in Table 2 . Among these six patients, only two patients had detectable HBsAg at the time of HBV DNA reappearance, at 14 and 20 months after LT, respectively (Cases 3 and 5). Serum HBV DNA and HBsAg again became negative in all six patients either spontaneously or following antiviral treatment and/or resection of recurrent metastatic HCC. Although HBV DNA reappearance was observed in six out of 32 patients, serum HBcrAg was detectable in 16 patients (50 %) after LT with a median level of 3.2 log U/mL (range 3.0-5.2 log U/mL) ( Table 3 ). These results indicated that HBV reinfection is more frequent than previously thought based on measurement of HBV DNA or HBsAg. No clinical factor at the time of LT was associated with HBcrAg positivity.
HCC recurrence and HBV DNA reappearance
In this study, 21 out of 32 patients had HCC at LT (Fig. 2a) . Among the 21 patients with HCC, five patients developed HCC recurrence during the observation period after LT. The mean HCC recurrence time was 15 months (range 7-67 months). Among the five patients with HCC recurrence, three patients (60 %) also developed HBV DNA reappearance. The cumulative HBV DNA reappearance rate was significantly higher in patients with HCC recurrence compared to those without HCC recurrence (p \ 0.001) (Fig. 2b) . One patient co-infected with HCV had HCC at LT. After LT the patient achieved sustained virological response for HCV following 72 weeks of peginterferon and ribavirin combination therapy and has not experienced HCC recurrence.
HBV S gene mutation in patients with HBV reinfection
Among the six patients with HBV reinfection, two patients did not experience HCC recurrence after LT (Cases 4 and 5) and one patient did not have HCC at the time of LT (Case 6) ( Table 2 ). To analyze the causes of HBV reinfection in these three patients, the sequence of the HBV S gene was analyzed. Although Case 4 showed no amino acid substitutions, Cases 5 and 6 showed G145R and C138R ? T140S ? G145A substitutions within the ''a'' determinant region, respectively (Fig. 3a) . HBV DNA in Case 5 was undetectable under LAM treatment at LT (Fig. 3b) ; however, both HBV DNA and HBsAg reappeared 18 months after LT. The LAM-resistant YIDD mutation was detected, and ADV therapy was started in conjunction with LAM, after which HBV DNA levels decreased below the detectable limit. Since both HBsAg and HBV DNA were negative under LAM plus ADV, HBIG, and HB vaccine treatments, whereas HBcrAg was positive, these treatments were discontinued. However, HBV DNA reappeared 1 month after cessation of the treatments. Sequencing analysis showed the presence of an HBV S G145R mutation in the serum prior to HBsAg decrease. No significant alanine aminotransferase (ALT) flare-up was observed throughout the clinical course.
Case 6 had been treated with LAM and ADV for YIDD mutation prior to LT. HBV DNA titer was 6.2 log copies/ mL at LT (Fig. 3c) . HBsAg and HBV DNA became negative under HBIG, LAM, and ADV therapies after LT. Since high HBsAb titer was maintained, HBIG administration and NA were stopped approximately 2 and 3 years after LT, respectively. HBV DNA reappeared 8 months after cessation of the treatments, and the HBV S G145A mutation was detected. However, serum HBV DNA became negative the following month without any antiviral treatment. HBV DNA and HBsAg levels remained below the cut-off level, but HBcrAg levels were positive. No significant ALT flare-up was observed throughout the clinical course.
HBIG treatment
All patients were administrated HBIG routinely to maintain serum HBsAb titer above the therapeutic level. HBIG treatment was stopped as a result of maintenance of high HBsAb titer in 15 out of the 32 patients. The cumulative rates of HBIG cessation were similar in HBcrAg-positive and HBcrAg-negative patients (Fig. 4a) . Case 7 had received HBIG treatment for 4 years after LT, and the treatment was stopped due to sustained high levels of HBsAb titer (Fig. 4b) . Although this patient was positive for serum HBcrAg, HBV DNA reappearance was not observed despite cessation of HBIG, HB vaccination, and LAM.
Discussion
In the study, although only six out of 32 patients developed HBsAg and/or HBV DNA reappearance during the observation period, HBcrAg was detected in 16 (50 %) patients. Thus, HBV reinfection seems to be more common than usually considered by conventional measurement of HBsAg and HBV DNA. A previous study demonstrated that HBV cccDNA was detectable in post LT patient livers even without HBV recurrence [21] . NA blocks the reverse transcription of HBV RNA to DNA, but cannot inhibit translation or transcription of viral RNA, and; therefore, cccDNA remains present in hepatocytes. The cccDNA episome is the transcriptional template for HBV messenger RNA. Therefore, cccDNA is recognized as an accurate marker for HBV DNA replication ability under NA therapy. HBcrAg is presumed to reflect the presence and quantity of cccDNA [16] , so it has been recently thought to be a useful risk marker for HBV resistance at the 6 month point after LAM cessation [22] . The presence of HCC at the time of LT and HCC recurrence after LT were independent risk factors for HBV reinfection [9, 10] . In our study, five out of six patients with HBV reinfection had HCC before LT, and three patients developed HCC recurrence after LT. Consistent with previous reports, the HBV reinfection rate was significantly higher in patients with HCC recurrence than in patients without HCC recurrence (Fig. 2b) . It has been reported that being positive for HBcrAg during NA therapy is an independent risk factor for development of HCC as well as HCC recurrence after curative therapy, and loss of HBcrAg by NA therapy resulted in a lower risk of HCC development [23, 24] . In the present study, two out of 14 HBcrAgpositive (14.3 %) and three out of seven HBcrAg-negative patients (42.8 %) developed HCC recurrence after LT; no significant correlation between HBcrAg positivity and HCC recurrence was observed at the time. Further analysis is needed to clarify the relationship between HBcrAg and HCC recurrence after LT.
The association between HCC and HBV reinfection suggests a role for HCC as a viral reservoir. Wong et al. reported that HBV cccDNA levels in tumor tissues were significantly higher than those in non-tumor tissues in HCC patients [21] . It was suggested that replication competent HBV DNA may be present in HCC, and HBV replication may occur in occult or recurrent extrahepatic metastatic sites and lead to HBV reinfection. In this study, one patient (Case 3) developed HBV DNA and HBsAg reappearance while remaining negative for HBcrAg (supplementary Fig. 1 ). In this case, HBsAg reappeared 14 months after LT without HBV DNA increase, and metastatic HCC recurrence was diagnosed in the lung. After surgical resection and chemotherapy for the lung metastasis, serum HBsAg titer decreased below the detectable limit. However, one year after surgical resection, HCC recurred in the pleura, and HBsAg again became positive. Although HBV DNA also reappeared, the levels were very low, and HBcrAg was not detected throughout the clinical course. In this case, it is possible that recurrent HCC worked as a viral reservoir. HBV-basal core promoter (BCP) mutation is a risk factor for HBV-related hepatocarcinogenesis. A recent report showed that the presence of BCP mutation before LT was an important factor related not only to HBV relapse but also HCC recurrence after LT [25] . In the present study, preoperative stored serum was available for four out of the five patients who experienced HCC recurrence after LT, and all four patients had BCP mutations. HBV recurrence can occur due to the development of escape mutations in the ''a'' determinant region of HBV after long-term suppression by HBIG [26, 27] . In this study, HBV escape mutations were detected in two out of three patients with HBV reappearance but without HCC or HCC recurrence (Fig. 3a) . The development of an escape mutation has been associated with poor clinical outcome [28] ; therefore, such patients should be treated with antiviral agents as soon as possible because HBIG is no longer effective.
HBsAb development rate by vaccination did not differ between HBcrAg-positive and HBcrAg-negative patients (Fig. 4a) . After HBIG cessation, HBV reinfection occurred in three of the eight HBcrAg-positive patients; in contrast, none of the seven HBcrAg-negative patients developed HBV reinfection. Further studies involving larger numbers of patients are required to investigate whether or not HBcrAg could be a marker for cessation of immunoglobulin and vaccine therapies after LT.
HBV DNA reinfection is likely to be caused by cessation of NA, emergence of NA-resistant HBV, HCC recurrence, and development of escape mutations. To prevent HBV reinfection, life-long NA therapy seems to be the most effective treatment. In fact, acquisition of HBsAb by HB vaccine treatment and continuation of NA is the only effective treatment to in order to discontinue HBIG [29] [30] [31] . However, long-term NA treatment has several drawbacks, including the high economic burden and the potential risk of multi-drug resistance, as well as the possibility unknown side effects. Case 7 showed the possibility of antiviral agent follow-up after LT even in HBcrAgpositive patients (Fig. 4b) . Considering these favorable outcomes, stopping NA treatment might be considered with proper patient selection and close monitoring. Regardless, new therapies to permit safe discontinuation of NA and HBIG safety are needed.
In conclusion, HBV reinfection after LT is more common than usually considered by conventional measurement of HBsAg and HBV DNA. HCC recurrence and HBV S gene mutations were associated with HBV reinfection after LT.
